-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2023-504736-18-00
10
2018-07-26
Moderately to Severely Active Crohn's Disease
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2023-504802-12-00
7
2018-05-16
Lymphoma of B-cell origin
-
2023-504581-29-00
7
2018-04-26
Multiple myeloma
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-507500-31-00
10
2017-08-22
Advanced or metastatic Non-small cell lung cancer (NSCLC)
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2023-509169-19-00
5
2017-07-11
Advanced ALK positive non-small cell lung cancer
-
2023-509359-15-00
5
2017-03-08
Relapsed or Refractory Chronic Lymphocytic Leukemia
-
2023-510298-33-00
4
2016-11-29
Prostate Cancer
-
2023-505034-10-00
4
2016-08-01
Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
-
2022-501017-31-00
5
2016-05-10
Rheumatoid arthritis
-
2024-515749-40-00
5
2016-02-25
Malignant melanoma of the skin in patients with locally advanced and f
-
2022-501253-37-00
4
2016-02-02
(A) Anal Squamous Cell Carcinoma,
(B) Biliary Adenocarcinoma (gallblad
-
2024-511040-58-00
6
2016-01-12
non small cell lung cancer
-
2023-509425-53-00
5
2015-11-09
Atopic Dermatitis
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-513454-29-00
5
2015-10-15
Non-Small Cell Lung Cancer (NSCLC)
-
2023-509347-27-00
5
2015-09-30
High Risk Chronic Lymphocytic Leukaemia
-
2024-513521-23-00
5
2015-08-19
Prostate Cancer
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2023-506781-30-00
5
2014-09-17
Breast cancer